Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV)

International Angiology

Volumn 24, Issue 1, 2005, Pages 64-69

  Meini, S ^a   De Franco, V ^a   Auteri, A ^a   Setacci, C ^a   Di Renzo, M ^a   Pieragalli, D ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Efficacy; Follow up; Iloprost; Ischaemia; Limb; Tolerability; Weekly infusion

Indexed keywords

ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; ILOPROST; METOCLOPRAMIDE;

ADULT; AGED; ANKLE PRESSURE; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; LIMB AMPUTATION; LIMB ISCHEMIA; LONG TERM CARE; MALE; MORTALITY; NAUSEA; PATIENT COMPLIANCE; PHLEBITIS; REST; SEX DIFFERENCE; SHORT COURSE THERAPY; SIDE EFFECT; TREADMILL EXERCISE; VOMITING; WALKING;

AGED; AGED, 80 AND OVER; EXERCISE TEST; FEMALE; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; ISCHEMIA; MALE; MIDDLE AGED; VASODILATOR AGENTS;

EID: 25444502045     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Krause W, Krais TH. Pharmacokinetics and pharmacodinamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986;30:61-8.
2. Knause W, Krais TH. Pharmacokinetics and pharmacodinamics of radio-labeled iloprost in elderly volunteers. Eur J Clin Pharmacol 1987;32:597-604.
3. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002;143:3207-10.
4. Bentzer P, Grande PO. Low-dose prostacyclin restores an increased protein permeability trauma in cat skeletal muscle. J Trauma 2004;56:385-92.
5. Mazzone A, Faggioli P, Cusa C, Stefanin C, Rondena M, Morelli B. Effects of iloprost on adhesion molecules and F1+2 in peripheral ischemia. Eur J Clin Invest 2002;32: 882-8.
6. Mazzone A, Mazzucchelli I, Fossati G. Iloprost effects on phagocytes in patients suffering from ischaemic diseases: in vitro evidence for down-regulation of αMβ2 integrin. Eur J Clin Invest 1966; 26:860-6.
7. Fisher CA, Kappa JR, Sinha AK. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1 on human platelet function. J Lab Clin Med 1987;109:184-90.
8. Czeslick EG, Simm S, Grond RE, Silber RE, Sablotski A. Inhibition of intracellular tumour necrosis factor (TNF)-α and IL-6 production in human monocytes by iloprost. Eur J Clin Invest 2003;33:1013-7.
9. Debey S, Kirchrath L, Schror K, Meyer-Kirchrath J. Ilo-prost down-regulates the expression of the growth regulatory gene Cyr61 in human vascular smooth muscle cells. Eur J Pharmacol 2003;474:161-4.
10. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marcé M, Losordo DW et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator activated receptors. J Mol Cell Cardiol 2004;36:363-70.
11. Bozkurt AK. Alpha-tocopherol and iloprost attenuate reperfusion injury in skeletal muscle ischemia/reperfusion injury. J Cardiovasc Surg 2002;43:693-6.
12. Alstaedt HO, Berzewski B, Breddin HK, Brockhaus W, Bruhn HD, Cachovan M et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 1993;49:573-8.
13. Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 1994;13:133-42.
14. GISAP Study Group. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). Int Angiol 1994;13:70-4.
15. Staben P, Albring M. Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: an open study in 900 patients. Prostaglandins Leukot Essent Fatty Acids 1996-154: 327-33.
16. Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C. Clinical and circulatory effects of iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III. Eur Rev Med Pharmacol Sci 1998;2:53-9.
17. DAWID Study Group. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. Vasa 1998;27: 15-9.
18. Ceriello A, Sardina M, Motz E, Lizzio S, Tuniz D, Bianchini C. Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III. Int J Angiol 1998;7:28-33.
19. Cappelli R, Bicchi M, Arrigucci S, Boschi S, Guerrini M, Forconi S. Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency. Minerva Cardioangiol 1999;47: 81-8.
20. Minnucci A, Agostinis M. Iloprost: a new simplified therapeutical regimen in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III and IV. Int Med 1999;7:87-9.
21. Duthois S, Cailleux N, Levesque H. Tolerance and therapeutic results of iloprost in obliterative arteriopathy in lower limbs at the severe chronic ischemia stage. A retrospective study of 29 consecutive cases. J Mal Vasc 2000;25:17-26.
22. Mazzone A, Vezzoli M, Ottini E, Montagna M, Mazzucchelli I, Dal Canton A. A new method of iloprost administration without a peristaltic pump. Curr Ther Res 2000;61:452-9.
23. Banyai S, Jenelten R, Wagner S, Allmann J, Banyai M, Koppensteiner R. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study. Int Angiol 2002;21:36-43.
24. Duthois S, Cailleux N, Benosman B, Levesque H. Tolerance of Iloprost and results of treatment of chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases. Diabetes Metab 2003;29:36-43.
25. Castagno PL, Mosso F, Carignano G, Leotta L, Apostolou D, Buzzacchino A. Trattamento con farmaci prostanoidi. G Ital Chir Vasc 2003;10:33-65.
26. TASC. Management of peripheral arterial disease. J Vasc Surg 2000;31:197-9.
27. Hildebrand M, Krause W. Pharmacokinetics of iloprost in patients with hepatic dysfunction. Int J Clin Pharmacol Ther Toxicol 1990;28:430-4.
28. Hildebrand M, Krause W, Fabian H, Koziol T, Neumayer HH. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. Int J Clin Pharmacol Res 1990;10:285-92.